SECURITIES AND EXCHANGE COMMISSION

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

________________

FORM 8-K
________________

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934


Date of report (Date of earliest event reported): April 23, 2003


ATHEROGENICS, INC.
(Exact Name of Registrant as Specified in its Charter)


Georgia

0-31261

58-210832

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

 


8995 Westside Parkway
 Alpharetta, GA  30004
(Address of principal executive offices)

Registrant's telephone number, including area code (678) 336-2500

_________________

 


Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits

            Exhibits.

            See Exhibit Index attached to this current report on Form 8-K.

Item 9.  Regulation FD Disclosure (furnished pursuant to Item 12, “Results of Operations and Financial Condition.”)

            On April 23, 2003, AtheroGenics, Inc. issued a press release to report the company’s financial results for the quarter ended March 31, 2003.  A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

____________________


2

SIGNATURES

 

            Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

 

ATHEROGENICS, INC.

 

 

 

 

Date:  April 23, 2003

By:  /s/MARK P. COLONNESE                    

 

            Mark P. Colonnese

 

            Senior Vice President of Finance and

 

            Administration and Chief Financial

 

            Officer

 

____________________

 

3

EXHIBIT INDEX

 

The following exhibit is filed as part of this current report on Form 8-K.

 

Exhibit No.

 

Description

 

 

 

99.1

–

Press Release dated April 23, 2003

 

 

 

4